Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
- 22 July 2025
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (8) , e649-e659
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisJournal of Thoracic Oncology, 2022
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryAnnals of Oncology, 2019
- Clinical outcomes of non–small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France studyEuropean Journal of Cancer, 2019
- BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsJournal of Thoracic Oncology, 2018
- Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutationsOncogene, 2018
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialThe Lancet Oncology, 2017
- Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutationCancer Medicine, 2017
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)The Lancet, 2016
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation ConsortiumCancer, 2014
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004